Results 81 to 90 of about 11,369 (213)

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

open access: yesFrontiers in Immunology, 2023
IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB.
Rūta Veinalde   +22 more
doaj   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta   +2 more
wiley   +1 more source

Macrophage delivered oncolytic virotherapy in triple negative breast cancer [PDF]

open access: yes
Background: Triple negative breast cancer (TNBC) is a high cause of morbidity and mortality. Novel treatments for TNBC are needed to extend the overall survival of patients with metastatic TNBC where the prognosis remains poor.
Kwan, Amy
core   +2 more sources

Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Immune‐cell dynamics in the tumor microenvironment converge on four major barriers to effective therapy: failed immune access, defective antigen visibility and priming, loss of effector maintenance, and suppressive tissue remodeling. These barriers emerge from local hypoxic, cytokine, metabolic, and stromal signals.
Pin Guo   +8 more
wiley   +1 more source

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

open access: yesAmerican Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting. Observations: A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy
Inta Jaunalksne   +4 more
doaj   +1 more source

Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?

open access: yesCancer Cell International, 2022
Viruses are completely dependent on host cell machinery for their reproduction. As a result, factors that influence the state of cells, such as signaling pathways and gene expression, could determine the outcome of viral pathogenicity.
Sara Shayan   +2 more
doaj   +1 more source

The evolving role of immunotherapy in ovarian cancer

open access: yesCancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani   +2 more
wiley   +1 more source

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

open access: yesJournal of Hematology & Oncology, 2021
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far ...
Johannes P. W. Heidbuechel   +1 more
doaj   +1 more source

Altitudinal Visual Field Defect as the Presenting Sign of a Brain Tumor: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Brain tumors present with symptoms depending on their type, location, and stage. Most cause visual field defects respecting vertical meridians. Compressive optic neuropathy may produce altitudinal defects, mimicking ischemic optic neuropathy.
Farid Shekarchian   +2 more
wiley   +1 more source

Evidence for oncolytic virotherapy: Where have we got to and where are we going? [PDF]

open access: yes, 2015
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal ...
Appleton, E   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy